Does anyone have any insight on the positions posted? How is management and overall morale? I have heard some fairly negative views, but hoping those are just disgruntled employees. Honest feedback please
Company is moving in the right direction as US became profitable for the first time last year. Lots of changes going on, most for the better. Historically, company had no direction but now plans are to grow both organically and through acquisition. Employees who typically looking to do things the old way and don't embrace change are not happy, however, the company is moving in the right direction with more positive changes to come
While the commentary above should be appreciated for the sincerity (I believe the poster is being genuine in his/her assessment) I would have to disagree. I would imagine most employees, past and present, would say the current leadership is seriously lacking direction. The US being profitable "for the first time last year" is just not a true statement as the overall business in the US has been profitable for many years (the above poster should read the internal annual report supplied to each employee which clearly states profitability, past and present, for each business unit around the globe). The recent Ulthera, Inc. purchase was costly ($600mm). Combined with anticipated loss in Namenda revenue (about $200mm annually), this is a sizable financial gamble for a company that just does not have the revenue stream to compensate for any mistakes. If you are in the US Aesthetics BU, you have to be excited about Ulthera and the investment. The Neurology BU has been a revolving door of incompetent leaders who are in way over their heads. Neurology continues to bleed cash and will never be a viable player in this space. The Dermatology BU is a complete mess with nothing in the pipeline and no acquisition prospects. It is a fact that Naftin is for sale. Generic 1% is about to hit the market. With the refusal to contract on 2%, very few PBMs will cover 2% on any tier once generic 1% is introduced and revenues will continue along the sliding scale they have been on over the past two years. If Merz can unload Naftin and get 2x-3x earnings on this old dog, the overall US business model will look much better.
First off, you are right. Everyone knows that the US business has been profitable for years. Let's move on from that point. Next, neurology is "Real" pharmaceuticals. No doubt, you in the US have it the hardest. It is not easy like the aesthetics bullshit, desperate soccer moms, private pay. Indications for drugs that lead to success have to be deemed as goal in all clinical trials. Otherwise you can not say shit to a physician or a provider. The PIB rules. That is reality. These goals were established 15 years ago. Errors from the start.
Although your comments are greatly appreciated, the internal annual report does not breakdown profitability by region. It only reports net revenue by region and EBITA on a corporate level.
Oh MM and GB THANK YOU! What are your qualifications again? Oh that's right " insert head directly in Bill's ass" . Your work history is a joke and it shows!
